uniQure N.V. (NASDAQ:QURE) Stock Has Consensus Target Price of $59.55

Key Points

• Analysts maintain a “Moderate Buy” consensus on uniQure, with 13 buy, two hold and one sell rating among 16 firms. The average 12-month price target is $59.55, above the reported share price of $38.23.
• uniQure reported a quarterly loss of $1.22 per share, missing the consensus estimate of $0.82, while revenue of $5.84 million exceeded expectations. Analysts expect a full-year loss of approximately $3.74 per share.
• Insiders sold 72,249 shares worth about $3.33 million over the past 90 days, while institutional investors and hedge funds own 78.83% of the company’s stock.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $59.55.

QURE has been the subject of several recent research reports. Weiss Ratings raised uniQure from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Wolfe Research raised shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a research note on Wednesday, July 29th. William Blair initiated coverage on shares of uniQure in a research report on Wednesday, September 2nd. They set an "outperform" rating for the company. Wall Street Zen downgraded shares of uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, September 5th. Finally, Barclays dropped their price target on shares of uniQure from $65.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, July 30th.

uniQure Stock Down 0.2%

NASDAQ:QURE opened at $38.23 on Friday. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -9.53 and a beta of 0.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The stock's fifty day moving average price is $44.58 and its two-hundred day moving average price is $32.99. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period last year, the business posted ($0.69) earnings per share. On average, analysts anticipate that uniQure will post -3.74 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, insider Walid Abi-Saab sold 30,000 shares of the company's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the completion of the sale, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 72,249 shares of company stock valued at $3,327,659. Company insiders own 4.65% of the company's stock.

Hedge Funds Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. increased its stake in uniQure by 107.3% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company's stock valued at $6,546,000 after purchasing an additional 73,566 shares in the last quarter. Royal Bank of Canada boosted its position in shares of uniQure by 26.0% during the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company's stock worth $1,763,000 after purchasing an additional 22,248 shares in the last quarter. Kalehua Capital Management LLC acquired a new position in shares of uniQure in the 1st quarter valued at $4,760,000. Voss Capital LP grew its holdings in shares of uniQure by 68.0% in the 4th quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company's stock valued at $5,025,000 after buying an additional 85,000 shares during the period. Finally, Orbimed Advisors LLC grew its holdings in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock valued at $34,926,000 after buying an additional 1,398,749 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure's pipeline has included AMT-130, an investigational gene therapy for Huntington's disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.